Clinical Trial

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-03-29; most recent amendment 2025-09-22.
Status change: Recruiting → Active, Not Recruiting 2025-05-26
Status change: Not Yet Recruiting → Recruiting 2022-08-22
Trial Details
NCT Number NCT05314010
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions Neuromyelitis Optica Spectrum Disorder
Enrollment 102 participants
Start Date 2022-08-18
Primary Completion 2025-02-21 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-25